SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROS

Core Viewpoint - Keros Therapeutics, Inc. is under investigation for potential securities fraud and unlawful business practices following significant stock price declines related to safety concerns in its clinical trials [1][2][3]. Group 1: Company Actions and Stock Performance - On December 12, 2024, Keros announced a voluntary halt in dosing for certain treatment arms in the TROPOS trial due to safety concerns, leading to a stock price drop of $50.22 per share, or 73.15$18.43 [2]. - On January 15, 2025, Keros further halted all dosing in the TROPOS trial based on ongoing safety reviews, resulting in an additional stock price decline of $2.06 per share, or 16.51$10.42 [3]. Group 2: Legal Investigation - Pomerantz LLP is investigating claims on behalf of Keros investors regarding potential securities fraud or other unlawful business practices by the company and its officers or directors [1].